Zambon Biotech Initiates Phase 3b Trial for Novel Parkinson's Disease Treatment IPX203
核心洞察
Zambon Biotech (搜索) has dosed the first patient in the European Phase 3b ADIP study evaluating IPX203, a novel modified-release levodopa/carbidopa formulation for advanced Parkinson's disease (搜索).
The randomized trial will compare IPX203 against standard immediate-release levodopa/carbidopa in 92 patients across Italy, Spain, and Poland over 25 weeks.
IPX203 features both immediate-release granules and extended-release beads designed to provide rapid onset and sustained therapeutic effect for patients with motor fluctuations (搜索).
Zambon Biotech (搜索) has announced the enrollment of the first patient in its European Phase 3b ADIP clinical study, marking a significant milestone in the development of IPX203, a novel oral modified-release formulation of levodopa/carbidopa for advanced Parkinson's disease (搜索). The trial represents the first Phase 3 evaluation of this specific dosing regimen for patients with moderate to severe motor fluctuations (搜索).
Novel Formulation Addresses Unmet Medical Need
IPX203 is designed to address limitations of current Parkinson's disease (搜索) treatments through its unique dual-release mechanism. The formulation contains both immediate-release granules and extended-release beads, providing rapid onset of action while sustaining the levodopa therapeutic effect for a longer duration compared to immediate-release levodopa/carbidopa. According to the World Health Organization, Parkinson's disease is the fastest growing neurological condition globally.
"Dosing the first person in our phase 3b ADIP study marks an important milestone for our company and for the people living with Parkinson's disease (搜索) who urgently need new therapies that truly improve their quality of life and the therapeutic outcomes," explained Dr. Mathias Knecht, Chief Medical Officer at Zambon Biotech (搜索).
Trial Design and Patient Population
The ADIP study is a Phase 3b open-label, active comparator, randomized clinical trial designed to assess the efficacy and safety of IPX203 in patients with advanced Parkinson's disease (搜索) and motor fluctuations (搜索). The study will compare IPX203 with standard immediate-release levodopa-carbidopa, focusing on improving ON time and reducing OFF time through personalized dosing schedules.
A key differentiator of the ADIP trial is its flexible dosing approach, which allows dosing intervals tailored to individual patient needs. This personalized strategy is expected to enhance symptom control and overall patient outcomes. The trial will enroll 92 patients across clinical sites in Italy, Spain, and Poland, running for up to 25 weeks including a 1-week screening period, 12-week treatment phase, and an optional 12-week extension.
Regulatory Progress and Commercial Strategy
Zambon Biotech (搜索) submitted IPX203 to the European Medicines Agency for regulatory approval in June 2025, following an exclusive licensing agreement with Amneal Pharmaceuticals for rights in the European Union, United Kingdom, and Switzerland. The company's strategy leverages the broader Zambon group's established commercialization capabilities and existing neurology footprint.
"Given our group's capabilities in commercialization and our existing footprint in neurology, particularly Parkinson's, we believe IPX203 could represent a valuable therapeutic option in Europe to improve the lives of moderate to severe Parkinson patients," said Dr. Frank Weber, Chief Executive Officer at Zambon Biotech (搜索).
Company Background and Pipeline Focus
Zambon Biotech (搜索) operates as a specialized division of the Zambon group, a multinational pharmaceutical company established in 1906 with 2,768 employees worldwide across 23 countries. The company reported revenue of 885 million euros in 2024 and maintains production facilities in Italy, Switzerland, China, Brazil, and France. Beyond its historical focus on respiratory diseases, urinary tract infections, and pain management, Zambon has expanded into neurodegenerative diseases (搜索) and rare conditions including cystic fibrosis (搜索) and bronchiolitis obliterans syndrome.